Journal issues > Issue 3, May 2021 > Indications and timing of neurosurgery for brain metastases in NSCLC

Indications and timing of neurosurgery for brain metastases in NSCLC

SUMMARY

Although prognosis of non-small cell lung carcinoma (NSCLC) patients with brain metastases (BMs) has improved over the last years, the overall survival remains poor. Indications for surgical resection of a single BM have been well defined in the literature: Limited and or controlled systemic disease, Karnofsky performance scale ≥70, solitary lesion larger than 3 cm, non-eloquent area of the brain and unclear pathological diagnosis. However, recent advances in surgical technique and intraoperative technologies have facilitated surgery, including surgery for multiple lesions and lesions in eloquent brain areas.^1–4 With the advance of molecularly targeted therapy, selection of patients who qualify for surgery of their BMs has become even more complex.⁵ The purpose of this review is to determine the indications and timing of surgery for brain metastases in NSCLC.

BELG J MED ONCOL 2021;15(3):104-11

To read the full artice you have the following options:

* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Oncology/Hemato-oncology in Belgium and Luxembourg with prescription authorisation)

Purchase this article for €3.03

** (for healthcare professionals with prescribing authorisation working outside the field of Oncology/Hemato-oncology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Oncology/Hemato-oncology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)

Top